Drug intelligence / Profile preview

SBRX21

Development stage: Preclinical
Lead developer: Stramsen Biotech

Overview

SBRX21 is a plant-based drug candidate developed by Stramsen Biotech for the treatment of pain associated with inguinal hernias in men. Developed using the company's proprietary medicinal plant database, SBRX21 is part of a pipeline of botanical therapeutics. As of current public disclosures, the specific active ingredients, molecular targets, and precise mechanism of action remain proprietary, though the drug is positioned for clinical evaluation in pain management.

Beyond the preview

Go deeper on SBRX21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBRX21.

Explore the full profile